SCHEMBL5042461

SCHEMBL5042461

COC(=O)c1cc(C(=NN)Nc2cccc(Cl)c2Cl)cn1S(C)(=O)=O

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.47
CYP2C19 P33261 3/20 0.47
PKM P14618 2/20 0.47
KMT2A Q03164 7/20 0.44
ALDH1A1 P00352 2/20 0.44
MAPK14 Q16539 5/20 0.41
MEN1 O00255 6/20 0.41
SMN1; SMN2 Q16637 2/20 0.38
POLB P06746 1/20 0.38
MAPK1 P28482 2/20 0.37
CXCR2 P25025 1/20 0.36
CX3CR1 P49238 1/20 0.36
MAPT P10636 3/20 0.36
LMNA P02545 2/20 0.36
NPC1 O15118 1/20 0.36
HPGD P15428 1/20 0.36
RAB9A P51151 1/20 0.36
KDM4E B2RXH2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5038310 0.83 SMN1; SMN2 (0.37) CYP1A2CYP2C19PKMKMT2AALDH1A1
SCHEMBL14278707 0.83 SMN1; SMN2 (0.37) CYP1A2CYP2C19PKMKMT2AALDH1A1
SCHEMBL5036604 0.76 PKM (0.46) CYP1A2CYP2C19PKMKMT2AALDH1A1
SCHEMBL5043490 0.72 PLA2G7 (0.37) KMT2AMEN1SMN1; SMN2POLBNPC1
SCHEMBL5033952 0.71 RAB9A (0.46) CYP1A2CYP2C19PKMKMT2AALDH1A1
SCHEMBL5041467 0.70 CYP1A2 (0.38) CYP1A2CYP2C19PKMKMT2AALDH1A1
SCHEMBL5041304 0.69 RAB9A (0.38) CYP1A2CYP2C19PKMKMT2AALDH1A1
SCHEMBL5033957 0.67 ALDH1A1 (0.38) CYP1A2CYP2C19PKMKMT2AALDH1A1
SCHEMBL9819481 0.64 KMT2A (0.62) KMT2AALDH1A1MEN1SMN1; SMN2POLB
SCHEMBL5042457 0.63 KMT2A (0.44) KMT2AALDH1A1MAPK14MEN1CXCR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7314885-B2 Pyrrole compounds useful as kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-01-01 US disclosed
US-20060173055-A1 (4-(4-(2,3-difluorophenyl)-4H-1,2,4-triazol-3-yl)-1H-pyrrol-2-yl)(2H-pyrrol-1(5H)-yl)methanone; anticarcinogenic, antiproliferative and antimetastasis agent; inhibitors of c-Met protein kinase VERTEX PHARMACEUTICALS INCORPORATED 2006-08-03 US disclosed
US-20050101650-A1 Pyrrole compositions useful as inhibitors of c-Met VERTEX PHARMACEUTICALS INCORPORATED 2005-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101650-A1 Pyrrole compositions useful as inhibitors of c-Met MET, PRKCH, DMPK CYP1A2 4341/4885CYP2C19 3011/4885PKM 237/4885
US-20060173055-A1 (4-(4-(2,3-difluorophenyl)-4H-1,2,4-triazol-3-yl)-1H-pyrrol-2-yl)(2H-pyrrol-1(5H)-yl)methanone; anticarcinogenic, antiproliferative and antimetastasis agent; inhibitors of c-Met protein kinase MET, DMPK, CDK4 CYP1A2 2453/4885CYP2C19 1840/4885PKM 195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.